Literature DB >> 3086027

Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease.

R C Walker, P J Ruane, J E Rosenblatt, D M Lyerly, C A Gleaves, T F Smith, P F Pierce, T D Wilkins.   

Abstract

Clostridium difficile culture, test tube, and microtiter cytotoxicity assays, and enzyme-linked immunosorbent assays (ELISAs) for toxin A and toxin B, were simultaneously performed on 113 fresh diarrheal stool specimens randomly selected from those submitted to our clinical laboratory for routine C. difficile testing. The performance of these tests in diagnosing C. difficile-related enteric disease (CDRED) was based on a clinical assessment of the likelihood of CDRED as determined by a systematic review of case histories blinded from the test results. Among 61 antibiotic recipients, both the microtiter cytotoxicity assay and the toxin A ELISA were highly specific for CDRED (95% and 100%, respectively). Specificities for the other procedures were much lower (tube cytotoxicity assay, 79%; culture, 74%; and toxin B ELISA, 56%). The high sensitivities of the culture (89%) and toxin B ELISA (83%) were somewhat negated by their low specificities. The only test that was both specific and had acceptable sensitivity (78%) was the microtiter cytotoxicity assay. This study indicates that ELISAs for detection of C. difficile toxins are not as reliable as the cytotoxicity assay in the laboratory diagnosis of CDRED, and that clinical correlation is essential in the evaluation of any new test for CDRED.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086027     DOI: 10.1016/0732-8893(86)90092-1

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  20 in total

1.  Monoclonal antibodies specific for Clostridium difficile toxin B and their use in immunoassays.

Authors:  F Müller; C Stiegler; U Hadding
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

2.  Evaluation of an enzyme immunoassay for detection of Clostridium difficile toxin A.

Authors:  K Tsimidis; A E Simor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-06       Impact factor: 3.267

3.  Evaluation of a new commercial Clostridium difficile toxin A enzyme immunoassay using diarrhoeal stools.

Authors:  M Delmée; T Mackey; A Hamitou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

4.  Re: Salvaging a linear staple line defect in ultra-low anterior resection.

Authors:  Y-H Ho
Journal:  Tech Coloproctol       Date:  2008-03       Impact factor: 3.781

5.  Evaluation of a new enzyme immunoassay for Clostridium difficile toxin A.

Authors:  S O Vargas; D Horensky; A B Onderdonk
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

Review 6.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

7.  Presumptive identification of Clostridium difficile by detection of p-cresol in prepared peptone yeast glucose broth supplemented with p-hydroxyphenylacetic acid.

Authors:  G Sivsammye; H V Sims
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

8.  Comparison of culture, cytotoxin assay and two EIA tests with clinical diagnosis of Clostridium difficile-associated diarrhea.

Authors:  M Binning; M A John; B C Schieven; T W Austin; R Lannigan; Z Hussain
Journal:  Can J Infect Dis       Date:  1994-07

9.  Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea.

Authors:  F Barbut; C Kajzer; N Planas; J C Petit
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

Review 10.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.